Concerns on Vaccine against Varicella Caused by Varicella-Zoster Virus Infection

[1]  Yuan-fang Chen,et al.  Varicella outbreak trends in school settings during the voluntary single-dose era from 2006 to 2017 in Shanghai, China. , 2019, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[2]  W. Straus,et al.  Varicella Virus Vaccine Live: A 22-Year Review of Postmarketing Safety Data , 2019, Open forum infectious diseases.

[3]  Guozhang Xu,et al.  Varicella breakthrough infection and effectiveness of 2-dose varicella vaccine in China. , 2018, Vaccine.

[4]  Yousheng Shu,et al.  Anterograde monosynaptic transneuronal tracers derived from herpes simplex virus 1 strain H129 , 2017, Molecular Neurodegeneration.

[5]  S. Rayner,et al.  ORF7 of Varicella-Zoster Virus Is Required for Viral Cytoplasmic Envelopment in Differentiated Neuronal Cells , 2017, Journal of Virology.

[6]  T. Yoshikawa,et al.  Safety profile of the varicella vaccine (Oka vaccine strain) based on reported cases from 2005 to 2015 in Japan. , 2016, Vaccine.

[7]  Lidia Oostvogels,et al.  Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. , 2016, The New England journal of medicine.

[8]  Min Zhang,et al.  Immunogenicity and safety of different schedules of 2-dose varicella vaccination in China , 2016, Human vaccines & immunotherapeutics.

[9]  K. Bhaskaran,et al.  Quantification of risk factors for postherpetic neuralgia in herpes zoster patients , 2016, Neurology.

[10]  R. Diefenbach,et al.  Dual Role of Herpes Simplex Virus 1 pUS9 in Virus Anterograde Axonal Transport and Final Assembly in Growth Cones in Distal Axons , 2015, Journal of Virology.

[11]  R. Cohrs,et al.  Varicella zoster virus infection , 2015, Nature Reviews Disease Primers.

[12]  L. Naldi,et al.  Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective , 2015, Therapeutic advances in vaccines.

[13]  Y. Jeon,et al.  Herpes Zoster and Postherpetic Neuralgia: Practical Consideration for Prevention and Treatment , 2015, The Korean journal of pain.

[14]  Shinn-Jang Hwang,et al.  Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. , 2015, The New England journal of medicine.

[15]  K. Kawai,et al.  Annual incidence rates of herpes zoster among an immunocompetent population in the United States , 2015, BMC Infectious Diseases.

[16]  K. Riedlinger,et al.  Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005-2009. , 2013, The Journal of infectious diseases.

[17]  R. S. Goldstein,et al.  ORF7 of Varicella-Zoster Virus Is a Neurotropic Factor , 2012, Journal of Virology.

[18]  Ivan S F Chan,et al.  Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  David J. Anderson,et al.  A Cre-Dependent, Anterograde Transsynaptic Viral Tracer for Mapping Output Pathways of Genetically Marked Neurons , 2011, Neuron.

[20]  A. Oaklander,et al.  Management of herpes zoster and post-herpetic neuralgia now and in the future. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[21]  V. Schuster,et al.  Immunogenicity and Safety Assessments After One and Two Doses of a Refrigerator-Stable Tetravalent Measles-Mumps-Rubella-Varicella Vaccine in Healthy Children During the Second Year of Life , 2008, The Pediatric infectious disease journal.

[22]  P. LaRussa,et al.  The safety profile of varicella vaccine: a 10-year review. , 2008, The Journal of infectious diseases.

[23]  P. Peduzzi,et al.  A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. , 2005, The New England journal of medicine.

[24]  C. Argoff,et al.  Treatment of postherpetic neuralgia: a review of therapeutic options. , 2004, Journal of pain and symptom management.

[25]  A. Arvin,et al.  Varicella-zoster virus , 1996, Clinical microbiology reviews.

[26]  T. Yoshikawa,et al.  Experience and reason: twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine. , 1994, Pediatrics.

[27]  W. Meschino,et al.  Outcome after maternal varicella infection in the first 20 weeks of pregnancy. , 1994, The New England journal of medicine.

[28]  K. Yamanishi,et al.  Viral replication and immunologic responses in children naturally infected with varicella-zoster virus and in varicella vaccine recipients. , 1985, The Journal of infectious diseases.

[29]  E. Scolnick,et al.  Live attenuated varicella virus vaccine. Efficacy trial in healthy children. , 1984, The New England journal of medicine.

[30]  Y. Okuno,et al.  Live vaccine used to prevent the spread of varicella in children in hospital. , 1974, Lancet.